A team of veteran international healthcare investors, advisors, medical device industry executives and a device inventor are patiently waiting for China s Food and Drug Administration to approve a portable insulin pump.
SHANGHAI – Beigene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers.
SHANGHAI – BeiGene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical candidate oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers.
BEIJING, China – Paul Grayson scoffs at the biopharma executives who trumpet their expensive search for new biologic targets to create completely novel, and crazily expensive biologics. He said that approach does not apply to cost-sensitive China and he is championing a new definition of "novel" biologics in his development of an antibody for rheumatoid arthritis and other products.
SHANGHAI, China – Chipscreen Biosciences Ltd., of Shenzhen, China, reported encouraging Phase II trial results for its Chidamide (formerly HBI-8000) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who had failed at least one prior systemic therapy.
SHANGHAI – As the S&P 500, the Dow Jones Industrial Average and the Nasdaq Biotechnology Index close at record highs, one might think that respectable Chinese biopharmas on the New York Stock Exchange or Nasdaq would be well positioned to enjoy the benefits of such a robust stock market. In fact, many are cutting their ties.
As the S&P 500, the Dow Jones Industrial Average and the Nasdaq Biotechnology Index close at record highs, one might think that respectable Chinese biopharmas on the New York Stock Exchange or Nasdaq would be well positioned to enjoy the benefits of such a robust stock market. In fact, many are cutting their ties.
SHANGHAI – In China, local med-tech manufacturers have successfully pushed multinationals' products to the side at least in some product lines, due to strong government incentives, their low cost and improved quality.
